Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel Failure.

CONCLUSION: There was no significant survival benefit for mitoxantrone plus prednisone over prednisone alone among men with mCRPC after docetaxel therapy. This finding is consistent with prior studies showing no survival advantage with mitoxantrone in the predocetaxel setting. Furthermore, our data suggest that mitoxantrone may be associated with increased toxicity compared with prednisone alone. PMID: 25888270 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/25888270?dopt=Abstract

Source: The Oncologist - April 17, 2015 Category: Cancer & Oncology Authors: K Green A, Corty R, A Wood W, Meeneghan M, Reeder-Hayes KE, Basch E, Milowsky MI, Dusetzina SB Tags: Oncologist Source Type: research